NCT02236715已完成不适用
Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Unit Dose Vial 500 µg in Chronic Obstructive Airways Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,039
- 主要终点
- Change in total severity of the clinical picture rated on a 4-point scale
研究概览
简要总结
Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease
- •Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion
排除标准
- •Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg
研究组 & 干预措施
Chronic Obstructive Airways Disease
干预措施: Atrovent® (Drug)
结局指标
主要结局
Change in total severity of the clinical picture rated on a 4-point scale
时间窗: after 4 weeks
次要结局
- Assessment of efficacy by patient on a 4-point scale(after 4 weeks)
- Assessment of tolerability by patient on a 4-point scale(after 4 weeks)
- Number of patients with adverse drug reactions(up to 4 weeks)
- Assessment of efficacy by investigator on a 4-point scale(after 4 weeks)
- Assessment of tolerability by investigator on a 4-point scale(after 4 weeks)
研究者
相似试验
已完成
不适用
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02238197Boehringer Ingelheim477
已完成
不适用
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02238171Boehringer Ingelheim346
已完成
不适用
Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02233894Boehringer Ingelheim526
已完成
不适用
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT02233881Boehringer Ingelheim4,222
已完成
不适用
Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways DiseasePulmonary Disease, Chronic ObstructiveNCT02238145Boehringer Ingelheim660